Previous Close | 43.15 |
Open | 43.07 |
Bid | 31.24 x 800 |
Ask | 69.32 x 1100 |
Day's Range | 42.59 - 43.50 |
52 Week Range | 32.51 - 72.31 |
Volume | |
Avg. Volume | 274,916 |
Market Cap | 1.989B |
Beta (5Y Monthly) | 1.24 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -1.12 |
Earnings Date | Feb 13, 2023 - Feb 17, 2023 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 63.60 |
MASON, Ohio, January 24, 2023--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that it will release its fourth quarter and full year 2022 financial results on Tuesday, February 21, 2023.
MASON, Ohio, January 09, 2023--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-operative pain management, announced preliminary financial results for the fourth quarter and full year 2022 and provided 2023 financial guidance.
Does the December share price for AtriCure, Inc. ( NASDAQ:ATRC ) reflect what it's really worth? Today, we will...